Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma-Reference-Cited by-同舟云学术

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

Published:2021-06 Issue:6 Volume:8 Page:e389-e392
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Bird Sarah,Panopoulou Aikaterini,Shea Robyn L,Tsui Micky,Saso Radovan,Sud Amit,West Sharon,Smith Katy,Barwood John,Kaczmarek Ewa,Panlaqui Carmela,Kaiser Martin,Stern Simon,Pawlyn Charlotte,Boyd Kevin

Funder

The National Institute for Health Research Biomedical Research Centre for cancer

Cancer Research UK

Wellcome Trust

Publisher

Elsevier BV

Subject

Hematology

Reference6 articles.

1. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy;Cook;Br J Haematol,2020

2. COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers;Hultcrantz;Blood Cancer Discov,2020

3. Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines;Monin-Aldama;medRxiv,2021

4. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial;Ramasamy;Lancet,2021

5. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates;Walsh;N Engl J Med,2020

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis;BMC Geriatrics;2024-05-08

2. Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients;Life;2024-03-15

3. Efficacy of COVID-19 Vaccines in Patients with Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-analysis;JMA Journal;2024

4. Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia;Blood Advances;2023-07-12

5. Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2;Blood Reviews;2023-07